

**ASX Announcement****IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 GASTRIC CANCER TRIAL**

---

- Final patient enrolled into HER-Vaxx Phase 2 gastric cancer trial
- The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses

**SYDNEY, Australia, 7 January 2021:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce completion of recruitment to the Phase 2 trial of its B-cell activating immunotherapy HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer.

Completion of recruitment follows the recent Independent Data Monitoring Committee (IDMC) review of HER-Vaxx Phase 2 interim analysis safety and efficacy data where the IDMC reported no safety concerns and viewed this preliminary data as strongly in favour of a HER-Vaxx survival effect. The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the study given the strong signal observed in the data. Following the guidance from the IDMC, Imugene reduced the overall number of patients required to complete the study to 36 patients, all of which have now completed their baseline visit.

Imugene's Managing Director and Chief Executive Officer Leslie Chong said, "I am excited to report that we have completed recruitment in the HER-Vaxx Phase 2 clinical trial. This is an important achievement for Imugene and the many medical professionals seeking treatments for patients with advanced gastric cancer who often have very few medical options. I look forward to completing the study and updating the market with clinical trial results."

HER-Vaxx is designed to produce an antibody response against a cancer growth signal receptor protein called HER-2 found on the cell surface in breast and gastric cancers.

The Phase 2 study will test the efficacy, safety and immune response in gastric cancer patients with metastatic gastric cancer overexpressing the HER-2 protein. The Phase 2 study randomised patients into two arms of either HER-Vaxx plus standard-of-care (chemotherapy) or standard-of-care alone. The primary endpoint is overall survival and secondary endpoint will be progression-free survival.

The Phase 2 trial is being conducted at sites across Asia, Eastern Europe and India where clinicians and patients have difficulty accessing treatments such as Herceptin® and Perjeta® marketed by Swiss multinational Roche Holding AG. There is also a high prevalence of gastric cancer in many of the countries selected.

Full study details can also be found on [clinicaltrials.gov](https://clinicaltrials.gov) under study ID: NCT02795988

For further information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter @TeamImugene

Follow us on Facebook @Imugene

Follow us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.